Khera Sahil, Panza Julio A
Division of Cardiology, Department of Medicine, Westchester Medical Center, New York Medical College, 100 Woods Road, Valhalla, NY 10595, USA.
Division of Cardiology, Department of Medicine, Westchester Medical Center, New York Medical College, 100 Woods Road, Valhalla, NY 10595, USA.
Heart Fail Clin. 2017 Jul;13(3):571-580. doi: 10.1016/j.hfc.2017.02.010. Epub 2017 May 6.
With the totality of data supporting coronary artery bypass graft (CABG) for mortality benefit, symptomatic angina, and quality of life improvement, CABG should be a class I indication for patients with ischemic cardiomyopathy and severe left ventricular dysfunction. As the population ages and more patients are referred for CABG, a careful risk-benefit assessment should be an important part of the consideration regarding revascularization strategies. A heart team approach is critical to arrive at the best decision for each patient. Age, alone, should not be a contraindication because there are data to support a reduction in cardiovascular mortality with CABG in older patients.
鉴于所有数据均支持冠状动脉旁路移植术(CABG)可带来死亡率降低、缓解症状性心绞痛以及改善生活质量等益处,对于患有缺血性心肌病和严重左心室功能障碍的患者,CABG应列为I类适应证。随着人口老龄化以及越来越多的患者被转诊接受CABG,在考虑血运重建策略时,仔细的风险效益评估应成为重要组成部分。心脏团队协作方法对于为每位患者做出最佳决策至关重要。仅年龄本身不应成为禁忌证,因为有数据支持老年患者接受CABG可降低心血管死亡率。